Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19642044 | 0.90 | CRHR1 (0.43) | PDE4DCRHR1CRHR2 | |
| SCHEMBL19641945 | 0.90 | CNR1 (0.39) | PDE4DCRHR1CACNA1HCNR2KDM4C | |
| SCHEMBL19641955 | 0.87 | ABL1 (0.40) | HDAC1HDAC2CNR2KDM4CNR3C2 | |
| SCHEMBL19207316 | 0.87 | PDE4D (0.40) | PDE4DBRD4CREBBPCRHR1CRHR2 | |
| SCHEMBL19641915 | 0.83 | NR3C2 (0.39) | PDE4DBRD4CACNA1HCNR2KDM4C | |
| SCHEMBL19641910 | 0.80 | CNR2 (0.37) | CNR2KDM4CANO1 | |
| SCHEMBL19641948 | 0.79 | NR3C2 (0.42) | KDM4CNR3C2ANO1 | |
| SCHEMBL19207315 | 0.77 | CRHR1 (0.42) | PDE4DCRHR1CRHR2 | |
| SCHEMBL19207255 | 0.77 | CNR1 (0.40) | PDE4DCRHR1CRHR2KDM4CCNR1 | |
| SCHEMBL28263874 | 0.77 | IKBKB (0.41) | BRD4CREBBPCRHR1CRHR2KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071451-B | Pyrazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | claimed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | claimed |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | claimed |
| US-20190119218-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-04-25 | — | — | US | claimed |
| EP-3464246-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | claimed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | claimed |
| CN-109071451-B | Pyrazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190119218-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190119218-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3464246-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119218-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | SLC1A1, SLC1A3, SLC1A2 | PDE4D 2412/4885BRD4 583/4885CREBBP 385/4885 |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | SLC1A1, SLC1A3, SLC1A2 | PDE4D 2412/4885BRD4 583/4885CREBBP 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.